Options mapped
Beta-thalassemia: options by country
Sourced options by country plus visit-prep questions for Beta-thalassemia. Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.
Options mappedRare diseaseLast checked June 2026
What this page does
Maps options by country
It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.
What it does not do
Does not choose treatment
It does not rank treatments, recommend a choice, or decide clinical fit.
Where it comes from
Built on trusted sources
Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.
Information to gather before the next visit
- Is the condition transfusion-dependent, and what is the transfusion burden?
- Is the discussion about reducing transfusions, chelation support, or a one-time gene therapy?
- Is the patient eligible for autologous transplant/gene-therapy evaluation?
- Is Casgevy being considered through managed access, commercial reimbursement, or a trial?
Trial-search terms to discuss
Options by country
Treatments by country
Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.
United States
- Luspatercept-aamt / Reblozyl; betibeglogene autotemcel / Zynteglo; exagamglogene autotemcel / Casgevy[1]FDA-approvedBeta-thalassemia requiring regular RBC transfusions; gene therapies require transplant/gene-therapy eligibility and product-specific criteria; Regular transfusion-dependent adult beta-thalassemia anemia for luspatercept; transfusion-dependent beta-thalassemia gene therapy contexts for Zynteglo/Casgevy. · Gene therapies require stem-cell collection, conditioning, infusion, and long-term follow-up. Luspatercept is not a substitute for RBC transfusions when immediate anemia treatment is needed. Confidence/conflicts: Medium-high. Reblozyl is FDA-label supported; Zynteglo source is manufacturer product page; Casgevy U.S. beta-thalassemia approval should be verified with FDA label in a future pass.
- Luspatercept-aamt / Reblozyl; betibeglogene autotemcel / Zynteglo; exagamglogene autotemcel / Casgevy[1]FDA-approvedBeta-thalassemia requiring regular RBC transfusions; gene therapies require transplant/gene-therapy eligibility and product-specific criteria; Regular transfusion-dependent adult beta-thalassemia anemia for luspatercept; transfusion-dependent beta-thalassemia gene therapy contexts for Zynteglo/Casgevy. · Gene therapies require stem-cell collection, conditioning, infusion, and long-term follow-up. Luspatercept is not a substitute for RBC transfusions when immediate anemia treatment is needed. Confidence/conflicts: Medium-high. Reblozyl is FDA-label supported; Zynteglo source is manufacturer product page; Casgevy U.S. beta-thalassemia approval should be verified with FDA label in a future pass.
- Luspatercept-aamt / Reblozyl; betibeglogene autotemcel / Zynteglo; exagamglogene autotemcel / Casgevy[1]FDA-approvedBeta-thalassemia requiring regular RBC transfusions; gene therapies require transplant/gene-therapy eligibility and product-specific criteria; Regular transfusion-dependent adult beta-thalassemia anemia for luspatercept; transfusion-dependent beta-thalassemia gene therapy contexts for Zynteglo/Casgevy. · Gene therapies require stem-cell collection, conditioning, infusion, and long-term follow-up. Luspatercept is not a substitute for RBC transfusions when immediate anemia treatment is needed. Confidence/conflicts: Medium-high. Reblozyl is FDA-label supported; Zynteglo source is manufacturer product page; Casgevy U.S. beta-thalassemia approval should be verified with FDA label in a future pass.
European Union
- Casgevy / exagamglogene autotemcel[2]EMA authorisedTDT in people aged 12 years and older; no matched related HSC donor condition in EU announcement context; TDT in people aged 12 years and over for Casgevy; EU Zynteglo no-current-authorisation caveat. · Casgevy (exagamglogene autotemcel) holds an EU conditional marketing authorisation since 9 Feb 2024 for transfusion-dependent beta-thalassemia age 12+ where HSCT is appropriate and no HLA-matched related donor is available (confirmatory-data obligation ~Aug 2026). Source: Casgevy EPAR https://www.ema.europa.eu/en/medicines/human/EPAR/casgevy
- Casgevy / exagamglogene autotemcel[2]EMA authorisedTDT in people aged 12 years and older; no matched related HSC donor condition in EU announcement context; TDT in people aged 12 years and over for Casgevy; EU Zynteglo no-current-authorisation caveat. · Casgevy (exagamglogene autotemcel) holds an EU conditional marketing authorisation since 9 Feb 2024 for transfusion-dependent beta-thalassemia age 12+ where HSCT is appropriate and no HLA-matched related donor is available (confirmatory-data obligation ~Aug 2026). Source: Casgevy EPAR https://www.ema.europa.eu/en/medicines/human/EPAR/casgevy
- Reblozyl / luspatercept[3]EMA authorisedTDT in people aged 12 years and older; no matched related HSC donor condition in EU announcement context; TDT in people aged 12 years and over for Casgevy; EU Zynteglo no-current-authorisation caveat. · Reblozyl (luspatercept) holds full EU authorisation since 25 Jun 2020 (indication extended Feb 2023) for adult transfusion-dependent AND non-transfusion-dependent beta-thalassemia anaemia. Source: Reblozyl EPAR https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl
- Reblozyl / luspatercept[3]EMA authorisedTDT in people aged 12 years and older; no matched related HSC donor condition in EU announcement context; TDT in people aged 12 years and over for Casgevy; EU Zynteglo no-current-authorisation caveat. · Reblozyl (luspatercept) holds full EU authorisation since 25 Jun 2020 (indication extended Feb 2023) for adult transfusion-dependent AND non-transfusion-dependent beta-thalassemia anaemia. Source: Reblozyl EPAR https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl
- Zynteglo / betibeglogene autotemcel[4]EMA marketing authorisation withdrawn (Mar 2022)TDT in people aged 12 years and older; no matched related HSC donor condition in EU announcement context; TDT in people aged 12 years and over for Casgevy; EU Zynteglo no-current-authorisation caveat. · Only Zynteglo (betibeglogene autotemcel) is genuinely EU not-authorised — its EU marketing authorisation was withdrawn in March 2022 at bluebird bio's request for commercial reasons (withdrawal does not mean unavailable in all jurisdictions). Casgevy (conditional MA since 9 Feb 2024) and Reblozyl (full MA since 25 Jun 2020) ARE authorised and are now shown as separate available records.
- Zynteglo / betibeglogene autotemcel[4]EMA marketing authorisation withdrawn (Mar 2022)TDT in people aged 12 years and older; no matched related HSC donor condition in EU announcement context; TDT in people aged 12 years and over for Casgevy; EU Zynteglo no-current-authorisation caveat. · Only Zynteglo (betibeglogene autotemcel) is genuinely EU not-authorised — its EU marketing authorisation was withdrawn in March 2022 at bluebird bio's request for commercial reasons (withdrawal does not mean unavailable in all jurisdictions). Casgevy (conditional MA since 9 Feb 2024) and Reblozyl (full MA since 25 Jun 2020) ARE authorised and are now shown as separate available records.
Australia
- luspatercept (Reblozyl)[5]TGA-registered (Australia)beta-globin / beta-thalassemia context; transfusion-dependent anemia; adult patients with transfusion-dependent anemia associated with beta thalassaemia. · The AusPAR's product information attachment may have been superseded; the current TGA PI/PBS status should be checked separately. This entry does not establish payer access or suitability. Confidence/conflicts: High for Australian luspatercept registration context; PBS and current PI remain source-pending. Availability/reimbursement outside the approving regulator not established.
- luspatercept (Reblozyl)[5]TGA-registered (Australia)beta-globin / beta-thalassemia context; transfusion-dependent anemia; adult patients with transfusion-dependent anemia associated with beta thalassaemia. · The AusPAR's product information attachment may have been superseded; the current TGA PI/PBS status should be checked separately. This entry does not establish payer access or suitability. Confidence/conflicts: High for Australian luspatercept registration context; PBS and current PI remain source-pending. Availability/reimbursement outside the approving regulator not established.
- regular blood transfusions; iron chelation therapy; genetic counseling / reproductive options[6]Standard option (per Healthdirect Australia)thalassaemia carrier/disease context; severity-dependent transfusion need; Australian general thalassaemia supportive-care and family-planning context. · Healthdirect is patient education and does not establish a drug label, transplant eligibility, or local hospital protocol. It does not distinguish every beta-thalassemia subtype. Confidence/conflicts: Medium-high for Australian supportive-care context; beta-thalassemia subtype-specific specialist guidance remains a gap.
- regular blood transfusions; iron chelation therapy; genetic counseling / reproductive options[6]Standard option (per Healthdirect Australia)thalassaemia carrier/disease context; severity-dependent transfusion need; Australian general thalassaemia supportive-care and family-planning context. · Healthdirect is patient education and does not establish a drug label, transplant eligibility, or local hospital protocol. It does not distinguish every beta-thalassemia subtype. Confidence/conflicts: Medium-high for Australian supportive-care context; beta-thalassemia subtype-specific specialist guidance remains a gap.
Thailand
- Deferasirox (Deferasirox Teva)[7]ApprovedBeta-thalassemia major or non-transfusion-dependent thalassemia syndrome; chronic iron overload context.; Chronic transfusional iron overload and selected non-transfusion-dependent thalassemia iron-overload contexts as stated in product information. · Product information does not establish Thai payer approval, monitoring logistics, renal/hepatic safety suitability, or individual chelation thresholds. Confidence/conflicts: High for Thai NDI-hosted indication text; payer and monitoring implementation remain gaps. No conflict recorded. Availability/reimbursement outside the approving regulator not established.
- Deferasirox; deferiprone; deferoxamine/desferrioxamine[8]ApprovedTransfusion-dependent thalassemia; age and prior-chelation context described in Thai NLEM conditions.; Iron-chelation access framework for transfusion-dependent thalassemia. · Thai-language NLEM text requires human review. This row describes access categories and conditions, not patient eligibility or dosing. Confidence/conflicts: Medium-high for NLEM access-condition text; human Thai-language review needed. No conflict recorded. Primary source is in Thai. English summary pending human review — confirm exact wording with your care team. Availability/reimbursement outside the approving regulator not established.
- Luspatercept (Reblozyl)[9]ApprovedBeta-thalassemia diagnosis; transfusion-dependent anemia.; Adult transfusion-dependent anemia associated with beta-thalassemia. · Product information does not establish Thai reimbursement, routine access, transfusion program availability, iron-chelation coverage, or suitability for individual patients. Confidence/conflicts: High for Thai NDI-hosted indication text; payer and broader supportive-care access remain gaps. No conflict recorded.
- Luspatercept (Reblozyl)[9]ApprovedBeta-thalassemia diagnosis; transfusion-dependent anemia.; Adult transfusion-dependent anemia associated with beta-thalassemia. · Product information does not establish Thai reimbursement, routine access, transfusion program availability, iron-chelation coverage, or suitability for individual patients. Confidence/conflicts: High for Thai NDI-hosted indication text; payer and broader supportive-care access remain gaps. No conflict recorded.
Canada
- exagamglogene autotemcel (Casgevy)[10]EMA authorisedhomozygous or compound heterozygous beta-thalassemia context; autologous CRISPR/Cas9-edited CD34+ cell therapy targeting BCL11A enhancer to increase fetal hemoglobin; Canadian TDT patients aged 12 years and older; treatment-centre and autologous stem-cell-transplant suitability apply. · This is a complex cell therapy requiring conditioning and long-term follow-up, not routine transfusion support. Health Canada authorization does not guarantee provincial coverage or access to a treatment centre. Confidence/conflicts: High for Canadian TDT authorization; payer and center implementation remain gaps. Availability/reimbursement outside the approving regulator not established.
- exagamglogene autotemcel (Casgevy)[10]EMA authorisedhomozygous or compound heterozygous beta-thalassemia context; autologous CRISPR/Cas9-edited CD34+ cell therapy targeting BCL11A enhancer to increase fetal hemoglobin; Canadian TDT patients aged 12 years and older; treatment-centre and autologous stem-cell-transplant suitability apply. · This is a complex cell therapy requiring conditioning and long-term follow-up, not routine transfusion support. Health Canada authorization does not guarantee provincial coverage or access to a treatment centre. Confidence/conflicts: High for Canadian TDT authorization; payer and center implementation remain gaps. Availability/reimbursement outside the approving regulator not established.
- exagamglogene autotemcel (Casgevy)[11]CADTH reimbursement recommendationdocumented homozygous or compound heterozygous beta-thalassemia, transfusion-dependence criteria per reimbursement review; Canadian public-drug-plan reimbursement-with-conditions context for TDT age 12+. · CDA-AMC recommendations are nonbinding for provincial/territorial plans. The recommendation includes one-time/no-retreatment and cost-reduction conditions; access also depends on specialized-centre capacity. Confidence/conflicts: Medium-high for reimbursement recommendation; local implementation remains source-pending.
- exagamglogene autotemcel (Casgevy)[11]CADTH reimbursement recommendationdocumented homozygous or compound heterozygous beta-thalassemia, transfusion-dependence criteria per reimbursement review; Canadian public-drug-plan reimbursement-with-conditions context for TDT age 12+. · CDA-AMC recommendations are nonbinding for provincial/territorial plans. The recommendation includes one-time/no-retreatment and cost-reduction conditions; access also depends on specialized-centre capacity. Confidence/conflicts: Medium-high for reimbursement recommendation; local implementation remains source-pending.
- exagamglogene autotemcel (Casgevy)[11]CADTH reimbursement recommendationdocumented homozygous or compound heterozygous beta-thalassemia, transfusion-dependence criteria per reimbursement review; Canadian public-drug-plan reimbursement-with-conditions context for TDT age 12+. · CDA-AMC recommendations are nonbinding for provincial/territorial plans. The recommendation includes one-time/no-retreatment and cost-reduction conditions; access also depends on specialized-centre capacity. Confidence/conflicts: Medium-high for reimbursement recommendation; local implementation remains source-pending.
- luspatercept (Reblozyl)[12]Health Canada approvedbeta-thalassemia-associated RBC transfusion-dependent anemia; adult Canadian patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia. · Product-monograph and SBD sources establish authorization, not provincial coverage or individual suitability. Pediatric use for beta-thalassemia was not authorized in the fetched monograph. Confidence/conflicts: High for Canadian Reblozyl authorization; coverage remains source-pending. Availability/reimbursement outside the approving regulator not established.
- luspatercept (Reblozyl)[12]Health Canada approvedbeta-thalassemia-associated RBC transfusion-dependent anemia; adult Canadian patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia. · Product-monograph and SBD sources establish authorization, not provincial coverage or individual suitability. Pediatric use for beta-thalassemia was not authorized in the fetched monograph. Confidence/conflicts: High for Canadian Reblozyl authorization; coverage remains source-pending. Availability/reimbursement outside the approving regulator not established.
- packed red blood cell transfusions; iron chelation therapy; allogeneic hematopoietic stem cell transplant; luspatercept[13]CADTH reimbursement recommendationbeta-thalassemia / transfusion-dependent phenotype; Canadian standard-of-care and comparator context for TDT. · This is health-technology-review clinical context, not a drug label or transplant referral rule. It should be paired with local hematology/transplant-center criteria and provincial coverage rules. Confidence/conflicts: Medium-high for Canadian standard-of-care context; local protocol and funding remain gaps.
- packed red blood cell transfusions; iron chelation therapy; allogeneic hematopoietic stem cell transplant; luspatercept[13]CADTH reimbursement recommendationbeta-thalassemia / transfusion-dependent phenotype; Canadian standard-of-care and comparator context for TDT. · This is health-technology-review clinical context, not a drug label or transplant referral rule. It should be paired with local hematology/transplant-center criteria and provincial coverage rules. Confidence/conflicts: Medium-high for Canadian standard-of-care context; local protocol and funding remain gaps.
Sources
- U.S. Food and Drug Administration — official drug label · official drug label
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- Therapeutic Goods Administration (TGA) — Australian Public Assessment Report · Australian Public Assessment Report
- Healthdirect Australia — Australian public health information · Australian public health information
- Thai National Drug Information / Thai FDA-MOPH — SmPC PDF / regulator drug-information repository · SmPC PDF / regulator drug-information repository
- Thai National Drug Information / Thai FDA-MOPH — national essential medicines list PDF / access policy · national essential medicines list PDF / access policy
- Thai National Drug Information / Thai FDA-MOPH — product information PDF / regulator drug-information repository · product information PDF / regulator drug-information repository
- Health Canada Drug and Health Product Portal — Summary Basis of Decision · Summary Basis of Decision
- CDA-AMC / CADTH via NCBI Bookshelf — reimbursement recommendation / health technology review · reimbursement recommendation / health technology review
- Health Canada Drug and Health Product Portal — Summary Basis of Decision · Summary Basis of Decision
- CDA-AMC / CADTH via NCBI Bookshelf — clinical review / health technology assessment · clinical review / health technology assessment
This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.
Beyond approved care
In clinical trials & emerging options
Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.
In clinical trials
- Luspatercept / Reblozyl; vebeglogene autotemcel; GMCN-508B LentiRed; BD211 gene-modified autologous HSCsClinical trial · NCT06073860Clinical trialTrial only (registry)Korea · Beta-thalassemia; TDT definitions in trials; postmarketing label-based luspatercept use in Korea; Korea label-based luspatercept use for beta-thalassemia/MDS postmarketing safety; China TDT autologous HSC gene-therapy trial contexts. · Korea registry supports approved-label use but does not replace the MFDS label. China gene therapies remain trial-framed in fetched records. Confidence/conflicts: High for registry cells; medium for Korea approval inference because the registry cites Korean approved label but primary MFDS label remains pending. ClinicalTrials.gov — postmarketing surveillance registry
- Luspatercept / Reblozyl; vebeglogene autotemcel; GMCN-508B LentiRed; BD211 gene-modified autologous HSCsClinical trial · NCT06073860Clinical trialTrial only (registry)Korea · Beta-thalassemia; TDT definitions in trials; postmarketing label-based luspatercept use in Korea; Korea label-based luspatercept use for beta-thalassemia/MDS postmarketing safety; China TDT autologous HSC gene-therapy trial contexts. · Korea registry supports approved-label use but does not replace the MFDS label. China gene therapies remain trial-framed in fetched records. Confidence/conflicts: High for registry cells; medium for Korea approval inference because the registry cites Korean approved label but primary MFDS label remains pending. ClinicalTrials.gov — postmarketing surveillance registry
- Luspatercept / Reblozyl; vebeglogene autotemcel; GMCN-508B LentiRed; BD211 gene-modified autologous HSCsClinical trial · NCT06073860Clinical trialTrial only (registry)Korea · Beta-thalassemia; TDT definitions in trials; postmarketing label-based luspatercept use in Korea; Korea label-based luspatercept use for beta-thalassemia/MDS postmarketing safety; China TDT autologous HSC gene-therapy trial contexts. · Korea registry supports approved-label use but does not replace the MFDS label. China gene therapies remain trial-framed in fetched records. Confidence/conflicts: High for registry cells; medium for Korea approval inference because the registry cites Korean approved label but primary MFDS label remains pending. ClinicalTrials.gov — postmarketing surveillance registry
- LentiGlobin BB305 drug product / betibeglogene autotemcel-related program; luspatercept; mitapivat; deferasirox formulations DST-0509/Jadenu/ExjadeClinical trial · NCT03207009Clinical trialTrial only (registry)Thailand · TDT; beta-thalassemia genotype and transfusion burden criteria vary by study; TDT gene-therapy and follow-up contexts; participants from prior luspatercept studies; transfusion-dependent alpha/beta-thalassemia for mitapivat; chelation-refractory transfusional iron overload for deferasirox study. · Several studies are completed or active-not-recruiting. Long-term follow-up studies do not administer investigational drug. Current reimbursement and product availability require national source verification. Confidence/conflicts: High for registry cells; no national approval claim is made from trial participation. ClinicalTrials.gov — clinical-trial registry
- LentiGlobin BB305 drug product / betibeglogene autotemcel-related program; luspatercept; mitapivat; deferasirox formulations DST-0509/Jadenu/ExjadeClinical trial · NCT03207009Clinical trialTrial only (registry)Thailand · TDT; beta-thalassemia genotype and transfusion burden criteria vary by study; TDT gene-therapy and follow-up contexts; participants from prior luspatercept studies; transfusion-dependent alpha/beta-thalassemia for mitapivat; chelation-refractory transfusional iron overload for deferasirox study. · Several studies are completed or active-not-recruiting. Long-term follow-up studies do not administer investigational drug. Current reimbursement and product availability require national source verification. Confidence/conflicts: High for registry cells; no national approval claim is made from trial participation. ClinicalTrials.gov — clinical-trial registry
- LentiGlobin BB305 drug product / betibeglogene autotemcel-related program; luspatercept; mitapivat; deferasirox formulations DST-0509/Jadenu/ExjadeClinical trial · NCT03207009Clinical trialTrial only (registry)Thailand · TDT; beta-thalassemia genotype and transfusion burden criteria vary by study; TDT gene-therapy and follow-up contexts; participants from prior luspatercept studies; transfusion-dependent alpha/beta-thalassemia for mitapivat; chelation-refractory transfusional iron overload for deferasirox study. · Several studies are completed or active-not-recruiting. Long-term follow-up studies do not administer investigational drug. Current reimbursement and product availability require national source verification. Confidence/conflicts: High for registry cells; no national approval claim is made from trial participation. ClinicalTrials.gov — clinical-trial registry
- LentiGlobin BB305 drug product / betibeglogene autotemcel-related program; luspatercept; mitapivat; deferasirox formulations DST-0509/Jadenu/ExjadeClinical trial · NCT03207009Clinical trialTrial only (registry)Thailand · TDT; beta-thalassemia genotype and transfusion burden criteria vary by study; TDT gene-therapy and follow-up contexts; participants from prior luspatercept studies; transfusion-dependent alpha/beta-thalassemia for mitapivat; chelation-refractory transfusional iron overload for deferasirox study. · Several studies are completed or active-not-recruiting. Long-term follow-up studies do not administer investigational drug. Current reimbursement and product availability require national source verification. Confidence/conflicts: High for registry cells; no national approval claim is made from trial participation. ClinicalTrials.gov — clinical-trial registry
A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.